Cumberland Pharmaceuticals CPIX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.13M-33.2% | $13.68M+65.0% | $8.29M-23.5% | $10.84M-7.5% | $11.71M+12.2% | ||
| $1.93M-13.7% | $2.24M+127% | $988.76K-50.8% | $2.01M+41.1% | $1.43M-27.9% | ||
| $7.2M-37.1% | $11.44M+56.6% | $7.3M-17.2% | $8.83M-14.2% | $10.29M+21.6% | ||
| 78.8%-4.8pp | 83.6%-4.5pp | 88.1%+6.6pp | 81.4%-6.4pp | 87.8%+6.8pp | ||
| $1.46M-5.9% | $1.55M+23.6% | $1.25M-14.6% | $1.47M+13.4% | $1.3M+0.2% | ||
| $5.06M-18.4% | $6.21M+40.0% | $4.43M+5.0% | $4.22M-0.2% | $4.23M+0.2% | ||
| $2.55M-36.7% | $4.04M+57.0% | $2.57M-10.5% | $2.87M+16.7% | $2.46M-26.0% | ||
| $1.25M+23.3% | $1.01M+0.4% | $1.01M+0.3% | $1.01M+0.1% | $1.01M-31.1% | ||
| $12.26M-18.5% | $15.05M+46.7% | $10.26M-11.5% | $11.58M+11.2% | $10.42M-15.1% | ||
| -$3.13M-128% | -$1.37M+30.2% | -$1.97M-163% | -$747.48K-158% | $1.29M+170% | ||
| -34.3%-24.2pp | -10%+13.7pp | -23.7%-16.8pp | -6.9%-17.9pp | 11%+28.7pp | ||
| $85.84K-24.0% | $112.94K+3.0% | $109.7K+0.1% | $109.55K-33.1% | $163.8K-26.6% | ||
| $78.03K-15.2% | $91.97K-30.1% | $131.58K+3.2% | $127.49K+1.4% | $125.71K+17.9% | ||
| -$146.08K— | —— | —— | —— | $0— | ||
| -$3.14M-125% | -$1.39M+28.4% | -$1.94M-166% | -$729.54K-158% | $1.25M+164% | ||
| $3.87K-83.3% | $23.25K+310% | $5.67K0.0% | $5.67K0.0% | $5.67K+110% | ||
| -$3.29M-133% | -$1.41M+27.3% | -$1.94M-162% | -$740.74K-159% | $1.26M+166% | ||
| -36%-25.7pp | -10.3%+13.1pp | -23.4%-16.6pp | -6.8%-17.6pp | 10.7%+29.0pp | ||
| -$0.22-144% | -$0.09+30.8% | -$0.13-160% | -$0.05-163% | $0.08+157% | ||
| -$0.22-144% | -$0.09+30.8% | -$0.13-160% | -$0.05-163% | $0.08+157% | ||
| 15M+0.7% | 14.9M-0.7% | 15M0.0% | 15M-2.0% | 15.3M+8.5% | ||
| 15M+0.7% | 14.9M-0.7% | 15M0.0% | 15M+0.1% | 14.9M+6.3% | ||
| $1.25M+23.3% | $1.01M+0.4% | $1.01M+0.3% | $1.01M+0.1% | $1.01M-31.1% | ||
| $9.13M-33.2% | $13.68M+65.0% | $8.29M-23.5% | $10.84M-7.5% | $11.71M+12.2% | ||
| -$3.13M-128% | -$1.37M+30.2% | -$1.97M-163% | -$747.48K-158% | $1.29M+170% | ||
| -$1.85M-463% | -$329.31K+64.5% | -$927.46K-424% | $286.44K-87.7% | $2.32M+772% | ||
| -$1.85M-463% | -$329.31K+64.5% | -$927.46K-424% | $286.44K-87.7% | $2.32M+772% | ||
| -20.3%-17.9pp | -2.4%+8.8pp | -11.2%-13.8pp | 2.6%-17.2pp | 19.8%+23.1pp | ||
| -$3.13M-128% | -$1.37M+30.2% | -$1.97M-163% | -$747.48K-158% | $1.29M+170% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cumberland Pharmaceuticals's revenue?
- Cumberland Pharmaceuticals (CPIX) generated $41.9M in revenue over the trailing twelve months, up 2.1% year over year.
- Is Cumberland Pharmaceuticals profitable?
- Cumberland Pharmaceuticals is not currently profitable: it reported a net loss of $7.4M over the trailing twelve months, a -17.6% net margin.
- What are Cumberland Pharmaceuticals's profit margins?
- Gross margin is 82.9% and operating margin is -17.2%, with a -17.6% net margin.
- What is Cumberland Pharmaceuticals's earnings per share?
- Cumberland Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.49.
- Where does Cumberland Pharmaceuticals's income statement data come from?
- Every line is extracted from Cumberland Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
